Multiple Myeloma: Sequencing Novel Therapies in Later Lines of Treatment
Focused discussion on the sequencing of bispecifics or CAR T-cell therapies in patients with multiply relapsed multiple myeloma.
Source: onclive.com
Stay updated with breaking news from Later Lines. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Focused discussion on the sequencing of bispecifics or CAR T-cell therapies in patients with multiply relapsed multiple myeloma.
The antibody-drug conjugate trastuzumab deruxtecan continues to show impressive progression-free and overall survival gains in previously treated unresectable and/or metastatic HER2+ breast cancer.